FOR RESEARCH ONLY! 5/19



BMS-986142


ALTERNATE NAME:

BMS986142

(2S,5R,3S)-6-fluoro-5-(3-(8-fluoro-1-methyl-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)-2-methylphenyl)-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide

| CATALOG #: | B2420-1 | 1 mg |
|------------|---------|------|
| | B2420-5 | 5 mg |

STRUCTURE:



| MOLECULAR FORMULA: | $C_{32}H_{30}F_2N_4O_4$ |
|--|--|
| MOLECULAR WEIGHT: | 572.61 |
| CAS NUMBER: | 1643368-58-4 |
| APPEARANCE: | White to off-white solid |
| PURITY: | ≥98% by HPLC |
| SOLUBILITY: | >40 mg/ml DMSO |
| STORAGE CONDITIONS: | -20°C |
| DESCRIPTION: | BMS-986142 is a potent, selective, and reversible BTK (Bruton's tyrosine kinase) inhibitor (BTK IC _{5 0} = 0.5 nM; human WB IC _{5 0} = 90 nM). BMS-986142 displays robust efficacy in murine models of rheumatoid arthritis (RA), including collagen-induced arthritis (CIA) and collagen antibody-induced arthritis (CAIA). |
| REFERENCES: | Watterson, S.H., et al. (2016). J. Med. Chem. 59, 9173-9200 Gillooly, K.M., (2017). PLoS One12(7): e0181782. |
| HANDLING: | Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure. |
| RELATED PRODUCTS: | |
| Evobrutinib (B2379) BTK Inhibitor, CNX-774 (2600) BTK Inhibitor, PCI-32765 (2298 | |

BTK Inhibitor, CNX-774 (2600) BTK Inhibitor, PCI-32765 (2298) AVL-292 (Spebrutinib) (9413) Acalabrutinib (B1193)

DISCLAIMER:

FOR RESEARCH USE ONLY! Not to be used on humans.